JP2019512210A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512210A5 JP2019512210A5 JP2018540833A JP2018540833A JP2019512210A5 JP 2019512210 A5 JP2019512210 A5 JP 2019512210A5 JP 2018540833 A JP2018540833 A JP 2018540833A JP 2018540833 A JP2018540833 A JP 2018540833A JP 2019512210 A5 JP2019512210 A5 JP 2019512210A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr
- domains
- domain
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 6
- 201000000849 skin cancer Diseases 0.000 claims description 5
- 239000003053 toxin Substances 0.000 claims description 5
- 231100000765 toxin Toxicity 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 102100032029 Epidermal growth factor-like protein 6 Human genes 0.000 claims description 4
- 101000921196 Homo sapiens Epidermal growth factor-like protein 6 Proteins 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 206010044285 tracheal cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 239000012216 imaging agent Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 7
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 108010093470 monomethyl auristatin E Proteins 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000223782 Ciliophora Species 0.000 description 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021139610A JP7358426B2 (ja) | 2016-02-05 | 2021-08-30 | Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法 |
| JP2023106822A JP2023130411A (ja) | 2016-02-05 | 2023-06-29 | Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法 |
| JP2024140677A JP2024164139A (ja) | 2016-02-05 | 2024-08-22 | Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291987P | 2016-02-05 | 2016-02-05 | |
| US62/291,987 | 2016-02-05 | ||
| PCT/US2017/016659 WO2017136807A1 (en) | 2016-02-05 | 2017-02-06 | Egfl6 specific monoclonal antibodies and methods of their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021139610A Division JP7358426B2 (ja) | 2016-02-05 | 2021-08-30 | Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019512210A JP2019512210A (ja) | 2019-05-16 |
| JP2019512210A5 true JP2019512210A5 (OSRAM) | 2020-03-12 |
Family
ID=59501106
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018540833A Pending JP2019512210A (ja) | 2016-02-05 | 2017-02-06 | Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法 |
| JP2021139610A Active JP7358426B2 (ja) | 2016-02-05 | 2021-08-30 | Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法 |
| JP2023106822A Pending JP2023130411A (ja) | 2016-02-05 | 2023-06-29 | Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法 |
| JP2024140677A Pending JP2024164139A (ja) | 2016-02-05 | 2024-08-22 | Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021139610A Active JP7358426B2 (ja) | 2016-02-05 | 2021-08-30 | Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法 |
| JP2023106822A Pending JP2023130411A (ja) | 2016-02-05 | 2023-06-29 | Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法 |
| JP2024140677A Pending JP2024164139A (ja) | 2016-02-05 | 2024-08-22 | Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10875912B2 (OSRAM) |
| EP (1) | EP3411070A4 (OSRAM) |
| JP (4) | JP2019512210A (OSRAM) |
| KR (1) | KR20180105704A (OSRAM) |
| CN (2) | CN109562163B (OSRAM) |
| AU (2) | AU2017214685B2 (OSRAM) |
| BR (1) | BR112018015826A2 (OSRAM) |
| CA (1) | CA3012696A1 (OSRAM) |
| MX (1) | MX2018009499A (OSRAM) |
| SG (1) | SG11201806622PA (OSRAM) |
| WO (1) | WO2017136807A1 (OSRAM) |
| ZA (1) | ZA201805051B (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017136807A1 (en) * | 2016-02-05 | 2017-08-10 | The Board Of Regents Of The University Of Texas System | Egfl6 specific monoclonal antibodies and methods of their use |
| CN111787946B (zh) * | 2017-10-01 | 2023-08-15 | 台北医学大学 | 抗-类egf结构域多重6(egfl6)抗体及其于癌症诊断及治疗中的应用 |
| CN113272327A (zh) | 2018-12-30 | 2021-08-17 | 豪夫迈·罗氏有限公司 | 抗兔cd19抗体及其使用方法 |
| CN110951733A (zh) * | 2019-11-27 | 2020-04-03 | 山西医科大学 | 一种靶向抑制食管癌EGFL6基因表达的siRNA及构建的表达载体和应用 |
| CN116381251B (zh) * | 2023-03-13 | 2024-06-25 | 柏定生物工程(北京)有限公司 | 一种肿瘤标志物诊断试剂盒及其诊断方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09503396A (ja) * | 1994-07-29 | 1997-04-08 | インノジェネティクス・エヌ・ブイ | 診断用及び治療用の精製ｃ型肝炎ウイルスエンベロープ蛋白 |
| US20030036508A1 (en) * | 1997-11-22 | 2003-02-20 | John Ford | EGF motif protein, EGFL6 materials and methods |
| EP1356045A2 (en) * | 2000-10-13 | 2003-10-29 | Nuvelo, Inc. | Egf motif protein, egfl6 materials and methods |
| JPWO2007060725A1 (ja) * | 2005-11-24 | 2009-05-07 | 財団法人阪大微生物病研究会 | 組換え多価ワクチン |
| AR059851A1 (es) * | 2006-03-16 | 2008-04-30 | Genentech Inc | Anticuerpos de la egfl7 y metodos de uso |
| CN110372792A (zh) | 2008-06-25 | 2019-10-25 | 艾斯巴技术-诺华有限责任公司 | 抑制vegf的稳定和可溶的抗体 |
| US8501197B2 (en) * | 2010-04-30 | 2013-08-06 | The Research Foundation for The State of New York | Compositions and methods for stimulating immune response against Moraxella catarrhalis |
| CA2849409A1 (en) * | 2011-09-23 | 2013-03-28 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Anti-tumor necrosis factor-alpha agents and uses thereof |
| WO2014150720A1 (en) * | 2013-03-15 | 2014-09-25 | The Regents Of The University Of Michigan | Compositions and methods relating to inhibiting cancer cell growth and/or proliferation |
| SG11201509609SA (en) * | 2013-05-24 | 2015-12-30 | Univ Texas | Chimeric antigen receptor-targeting monoclonal antibodies |
| WO2017136807A1 (en) * | 2016-02-05 | 2017-08-10 | The Board Of Regents Of The University Of Texas System | Egfl6 specific monoclonal antibodies and methods of their use |
-
2017
- 2017-02-06 WO PCT/US2017/016659 patent/WO2017136807A1/en not_active Ceased
- 2017-02-06 CN CN201780015519.9A patent/CN109562163B/zh active Active
- 2017-02-06 AU AU2017214685A patent/AU2017214685B2/en active Active
- 2017-02-06 CA CA3012696A patent/CA3012696A1/en active Pending
- 2017-02-06 KR KR1020187024950A patent/KR20180105704A/ko not_active Ceased
- 2017-02-06 BR BR112018015826A patent/BR112018015826A2/pt active Search and Examination
- 2017-02-06 MX MX2018009499A patent/MX2018009499A/es unknown
- 2017-02-06 US US16/075,711 patent/US10875912B2/en active Active
- 2017-02-06 JP JP2018540833A patent/JP2019512210A/ja active Pending
- 2017-02-06 SG SG11201806622PA patent/SG11201806622PA/en unknown
- 2017-02-06 EP EP17748334.4A patent/EP3411070A4/en active Pending
- 2017-02-06 CN CN202110985801.8A patent/CN113912717B/zh active Active
-
2018
- 2018-07-26 ZA ZA2018/05051A patent/ZA201805051B/en unknown
-
2020
- 2020-11-12 US US17/096,280 patent/US12152071B2/en active Active
-
2021
- 2021-08-30 JP JP2021139610A patent/JP7358426B2/ja active Active
-
2023
- 2023-06-29 JP JP2023106822A patent/JP2023130411A/ja active Pending
-
2024
- 2024-05-29 AU AU2024203614A patent/AU2024203614A1/en active Pending
- 2024-08-22 JP JP2024140677A patent/JP2024164139A/ja active Pending
- 2024-10-18 US US18/920,268 patent/US20250145702A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112020015479A2 (pt) | Anticorpos anticlaudina 18.2 e usos dos mesmos | |
| JP2020501531A5 (OSRAM) | ||
| JP2019509976A5 (OSRAM) | ||
| JP2013502913A5 (OSRAM) | ||
| JP2019535250A5 (OSRAM) | ||
| RU2016111015A (ru) | НУКЛЕИНОВЫЕ КИСЛОТЫ, КОДИРУЮЩИЕ АНТИТЕЛА ПРОТИВ СИАЛИРОВАННОГО АНТИГЕНА ЛЬЮИСАа ЧЕЛОВЕКА | |
| JP2019512210A5 (OSRAM) | ||
| JP2019502405A5 (OSRAM) | ||
| JP2010535713A5 (OSRAM) | ||
| JPWO2019173420A5 (OSRAM) | ||
| JP2012519492A5 (OSRAM) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2018512175A5 (OSRAM) | ||
| JP2017535257A5 (OSRAM) | ||
| TWI797609B (zh) | 抗pd-1和pd-l1的四價雙特異性抗體 | |
| US20250034275A1 (en) | Anti-trop-2 antibody or antigen-binding fragment thereof | |
| JP2024016024A5 (OSRAM) | ||
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| CN113039208A (zh) | 一种抗pd-l1抗原结合蛋白及其应用 | |
| CN116940598A (zh) | 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体 | |
| US20230340119A1 (en) | Composition of triax antibodies and method of making and using thereof | |
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| CN115594762A (zh) | 一种铁蛋白重链抗体及其用途 | |
| JPWO2019217145A5 (OSRAM) | ||
| CN115190887A (zh) | 结合cd47的抗原结合多肽及用途 |